← Back to headlines
Regeneron Adjusts Strategy Amid Mixed Clinical Trial Results for Melanoma Drug
The pharmaceutical company is recalibrating its development pipeline and trial protocols after evaluating intermediate data showing inconsistent efficacy for its cancer treatment candidate.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
